openPR Logo
Press release

Malignant Pleural Effusion Market Across the 7MM to Witness Promising Growth Through 2034 | DelveInsight

03-25-2025 02:12 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Malignant Pleural Effusion Market Across the 7MM to Witness

Leading Malignant Pleural Effusion companies in the market include - RS Oncology, Genelux Corporation, Candel Therapeutics, and others.

The Malignant Pleural Effusion Market is projected to experience steady growth at a decent CAGR through 2034 The malignant pleural effusion landscape is currently characterized by the absence of approved pharmacological interventions, with traditional drainage procedures dominating treatment approaches. This creates significant opportunities for pharmaceutical innovators to address unmet needs in this oncological complication which affects thousands of cancer patients worldwide. Key companies advancing therapeutic solutions in this area include RS Oncology, Genelux Corporation, and Candel Therapeutics, among others, with some promising candidates progressing through various stages of clinical development.

DelveInsight's "Malignant Pleural Effusion Market Insight, Epidemiology and Market Forecast 2034 [https://www.delveinsight.com/report-store/malignant-pleural-effusion-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides a detailed analysis of market trends, epidemiological patterns, and therapeutic development across the 7MM. The United States represents the largest segment of the malignant pleural effusion market, accounting for approximately 38% of incident cases within the analyzed regions. Among European countries, Among European countries, Germany has the highest proportion of diagnosed cases, while Spain has the lowest share of diagnosed cases.

Download the malignant pleural effusion market report to understand which factors are driving the malignant pleural effusion therapeutic market @ Malignant Pleural Effusion Market Trends [https://www.delveinsight.com/sample-request/malignant-pleural-effusion-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Among total malignant pleural effusion incident cases in the US, approximately 75% receive a formal diagnosis, while 25% remain undetected. When analyzed by tumor type, lung cancer leads to the highest incidence of malignant pleural effusion, responsible for around 30% of total cases attributed to this cancer type in 2023 across the 7MM.

The report also examines the current and emerging malignant pleural effusion treatment landscape. At present, the market lacks approved pharmacological interventions specifically targeting this condition, with drainage procedures considered the standard of care across treatment centers.

Discover evolving trends in the malignant pleural effusion treatment landscape @ Malignant Pleural Effusion Therapeutics Market [https://www.delveinsight.com/sample-request/malignant-pleural-effusion-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Malignant pleural effusion occurs when fluid containing cancer cells accumulates between the chest wall and the lung, resulting in symptoms such as difficulty breathing and chest discomfort. Current diagnostic approaches include cytological examination of fluid samples, histological assessment of tissue biopsies, and advanced imaging techniques like ultrasound, computed tomography, PET scans, and thoracoscopy.

Current treatment approaches focus primarily on symptom management rather than targeted modification of the disease. Therapeutic strategies usually involve conservative methods including repeated thoracentesis, pleurodesis, or the placement of indwelling pleural catheters. Additional interventions may include chemotherapy, radiation therapy, or the direct administration of medication to the pleural space, with sclerosing agents sometimes used in recurrent cases to induce pleural fibrosis and prevent fluid reaccumulation.

In early March 2025, the American Society of Clinical Oncology (ASCO) released updated guidelines for the treatment of malignant pleural mesothelioma. These updated guidelines emphasize a more nuanced approach to surgery, integration of immunotherapy, importance of genetic testing, and refined pathologic insights

Although the therapeutic pipeline for malignant pleural effusion is relatively limited, there have been some promising advancements. In September 2024, the U.S. FDA approved KEYTRUDA (Merck) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma. Additionally, RS Oncology launched a Phase II dose expansion in the MITOPE study for RSO-021 in February 2024. Other companies with potential interest in this therapeutic area include Genelux Corporation and Candel Therapeutics. The scarcity in the therapeutic pipeline offers substantial opportunities for pharmaceutical companies willing to invest in this area.

Unlock which malignant pleural effusion drug is expected to capture the largest market share in 7MM by 2034. Visit the Malignant Pleural Effusion Market Insights [https://www.delveinsight.com/sample-request/malignant-pleural-effusion-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

DelveInsight's report underscores that the limited number of companies engaging in this therapeutic area could significantly impact future market dynamics. RS Oncology's progress through clinical trials may attract interest from larger pharmaceutical companies, potentially transforming the malignant pleural effusion therapeutic landscape in the coming years. The report also highlights that effectively addressing this condition requires a balance between providing symptomatic relief and implementing targeted approaches to manage the underlying malignancy, presenting both challenges and opportunities for stakeholders in this evolving treatment space.

Table of Contents

1

Key Insights

2

Report Introduction

3

Malignant Pleural Effusion Market Overview at a Glance

4

Executive Summary of Malignant Pleural Effusion

5

Epidemiology and Market Methodology

6

Disease Background and Overview

7

Malignant Pleural Effusion Diagnosis

8

Malignant Pleural Effusion Treatment

9

Conclusion

10

Malignant Pleural Effusion Epidemiology and Patient Population

11

Malignant Pleural Effusion Patient Journey

12

Key Endpoints in Malignant Pleural Effusion Clinical Trials

13

Malignant Pleural Effusion Emerging Therapies

14

Malignant Pleural Effusion: 7 Major Market Analysis

15

KOL Views

16

SWOT Analysis

17

Malignant Pleural Effusion Unmet Needs

18

Appendix

19

DelveInsight Capabilities

20

Disclaimer

21

About DelveInsight

Related Reports

Malignant Pleural Effusion Pipeline Insights [https://www.delveinsight.com/report-store/malignant-pleural-effusion-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Malignant Pleural Effusion Pipeline Insight provides comprehensive insights about the Malignant Pleural Effusion pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Malignant Pleural Effusion companies, including LIPAC Oncology, RS Oncology, Clover Biopharmaceuticals, Gongwin Biopharm Holdings, Merk, and Simcere Pharmaceutical Group among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=malignant-pleural-effusion-market-across-the-7mm-to-witness-promising-growth-through-2034-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Malignant Pleural Effusion Market Across the 7MM to Witness Promising Growth Through 2034 | DelveInsight here

News-ID: 3936715 • Views:

More Releases from ABNewswire

Axial Spondyloarthritis Market: Epidemiology, Therapies, and Key Players | UCB, AbbVie, Pfizer, Amgen, Janssen Biotech, Pozen, Iroko Pharmaceuticals, Syntex Pharmaceuticals, Horizon Pharma, Eli Lilly,
Axial Spondyloarthritis Market: Epidemiology, Therapies, and Key Players | UCB, …
According to DelveInsight's estimates, the total prevalent population of axial spondyloarthritis was approximately 4,575,000 in 2023 in the 7MM, and these cases are expected to significantly increase during the study period [2020-2034]. Emerging therapies for axial spondyloarthritis, including SIMPONI (golimumab), XELJANZ (tofacitinib), CIMZIA (certolizumab pegol), ENBREL (etanercept), RINVOQ (upadacitinib), COSENTYX (secukinumab), TALTZ (ixekizumab), LUMICEF (brodalumab), BIMZELX (bimekizumab), and others, are expected to drive growth in the axial spondyloarthritis market in the
Acute Respiratory Distress Syndrome Market: Epidemiology, Therapies, and Key Players | Veru Inc., Direct Biologics, Athersys, Healios, MediciNova
Acute Respiratory Distress Syndrome Market: Epidemiology, Therapies, and Key Pla …
In 2023, the Acute Respiratory Distress Syndrome Market Size was highest in the US among the 7MM accounting for approximately USD 1,643 million that is further expected to increase at a CAGR of 3.6%. Emerging therapies for Acute Respiratory Distress Syndrome (ARDS), including Sabizabulin (Veru-111), ExoFlo (DB-001), and others, are anticipated to drive significant growth in the ARDS market in the coming years. DelveInsight has introduced its latest report, "Acute Respiratory Distress
Atypical Hemolytic Uremic Syndrome Market: Epidemiology, Therapies, and Key Players | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical
Atypical Hemolytic Uremic Syndrome Market: Epidemiology, Therapies, and Key Play …
The United States accounted for the highest Atypical Hemolytic Uremic Syndrome market size among the 7MM in 2023, expected to increase by 2034 with a CAGR of approximately 4% during the forecast period (2024-2034). Emerging therapies for Atypical Hemolytic Uremic Syndrome (aHUS), including Crovalimab (RG6107; SKY59), FABHALTA (iptacopan), and others, are expected to drive significant growth in the aHUS market in the coming years. DelveInsight has released a new report, "Atypical Hemolytic
Alzheimer's Disease Market: Epidemiology, Therapies, and Key Players | Anavex Life Sciences Corp., TauRx Therapeutics Ltd, BioVie Inc., AriBio Co., Ltd., Novo Nordisk A/S, AgeneBio, Neurim Pharmaceuti
Alzheimer's Disease Market: Epidemiology, Therapies, and Key Players | Anavex Li …
Alzheimer's Disease companies are Eisai Inc., T3D Therapeutics, Merck Sharp & Dohme, Shanghai Hengrui Pharmaceutical, NeuroSense Therapeutics, Pharmazz, Johnson & Johnson Innovative Medicine, NKGen Biotech, LEXEO Therapeutics, Inventage Lab, Neumora Therapeutics, Takeda, Perha Pharmaceuticals, Luye Pharma Group Ltd., Eli Lilly and Company, Prothena, Therabest Korea, Neurotez, TRIMTECH Therapeutics, Lexeo Therapeutics, and others. Emerging therapies for Alzheimer's Disease, including AR1001, AGB101, AMX0035, IVL3003, BHV-8000, and others, are expected to drive substantial growth

All 5 Releases


More Releases for Malignant

Malignant Mesothelioma Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Malignant Mesothelioma Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion. The impact of manufacturers on the market is significant across various industries, influencing supply chains, consumer choices, and economic growth. Manufacturers are key players in
Adult Malignant Glioma Therapeutics Market - Defying the Tumor, Empowering Survi …
Newark, New Castle, USA - new report, titled Adult Malignant Glioma Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Adult Malignant Glioma Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Adult Malignant Glioma Therapeutics market. The report offers
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections-Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape. Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.   Report Highlights Publisher's Pharmaceutical
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape. Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result,
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Malignant Melanoma 2. Malignant Melanoma Drug Mechanism of Action 3. Global Malignant Melanoma Market Analysis 3.1 Current Market Scenario 3.2 Global Malignant Melanoma Pipeline Overview 4. Global Malignant Melanoma Drug Market Dynamics 4.1 Favorable Market Parameters 4.2 Commercialization Challenges 5. Global Malignant Melanoma Drug Market Future Prospects 6. Global Malignant Melanoma Clinical Pipeline By
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there